KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Net Income (2018 - 2025)

Historic Net Income for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$501000.0.

  • Castle Biosciences' Net Income fell 12208.02% to -$501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 30085.6%. This contributed to the annual value of $18.2 million for FY2024, which is 13174.92% up from last year.
  • Per Castle Biosciences' latest filing, its Net Income stood at -$501000.0 for Q3 2025, which was down 12208.02% from $4.6 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Net Income registered a high of $9.6 million during Q4 2024, and its lowest value of -$29.2 million during Q1 2023.
  • For the 5-year period, Castle Biosciences' Net Income averaged around -$8.4 million, with its median value being -$6.4 million (2021).
  • Its Net Income has fluctuated over the past 5 years, first tumbled by 103938.11% in 2023, then skyrocketed by 47170.54% in 2024.
  • Castle Biosciences' Net Income (Quarter) stood at -$6.4 million in 2021, then tumbled by 220.65% to -$20.6 million in 2022, then skyrocketed by 87.49% to -$2.6 million in 2023, then soared by 471.71% to $9.6 million in 2024, then crashed by 105.22% to -$501000.0 in 2025.
  • Its last three reported values are -$501000.0 in Q3 2025, $4.6 million for Q2 2025, and -$25.8 million during Q1 2025.